Tsuda Toyonobu, Hayashi Kenshi, Kato Takeshi, Kusayama Takashi, Nakagawa Yoichiro, Nomura Akihiro, Tada Hayato, Usui Soichiro, Sakata Kenji, Kawashiri Masa-Aki, Fujino Noboru, Yamagishi Masakazu, Takamura Masayuki
Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences.
Kaga Medical Center.
Circ J. 2025 Jan 24;89(2):164-173. doi: 10.1253/circj.CJ-24-0132. Epub 2024 Aug 27.
Anemia, a common comorbidity in older patients with heart failure (HF) and atrial fibrillation (AF), is associated with an increased risk of adverse events. This study evaluated the prognostic effects of longitudinal changes in anemia status on clinical outcomes in patients with AF.
We prospectively evaluated data of 1,388 patients with AF from the Hokuriku-Plus AF Registry (1,010 men; mean [±SD] age 72.3±9.7 years) and recorded the incidence of death, HF, thromboembolism, and major bleeding. Of these patients, the 1,233 for whom hemoglobin levels were available at baseline and at the 1-year follow-up were further evaluated. Patients were categorized into 3 groups based on longitudinal changes in 1-year anemia status: Group 1, AF without anemia; Group 2, AF with improved anemia; and Group 3, AF with sustained or new-onset anemia. Over the 1-5 years of follow up, the incidences of death, HF, thromboembolism, and major bleeding were significantly higher among patients with than without anemia. In addition, the incidence of death or HF was significantly higher in Group 3 than in Groups 1 and 2. Multivariate analysis revealed no anemia or improvement in anemia in 1 year as an independent predictor for a favorable prognosis for cardiovascular death and HF.
Recovery from anemia may be associated with a favorable clinical course of AF.
